Absci vs Generate Biomedicines (2026)
Absci and Generate Biomedicines both use generative models and their own laboratories to design protein therapeutics they then develop, and coverage of de novo antibody design and of AI antibody discovery names them together, as does CB Insights. Generate is further along in the clinic. Absci designs antibodies against chosen epitopes with Origin-1 and tests them in its Vancouver, Washington lab, with ABS-201 in a Phase 1/2a trial for pattern hair loss and endometriosis next; it partners selectively, and Eli Lilly invested $40 million in 2026. Generate's Chroma model, published in Nature in 2023, generates protein structures and sequences, and its loop has produced more than 42,000 tested proteins. GB-0895, an anti TSLP antibody for severe asthma designed for twice yearly dosing, entered Phase 3 in January 2026, and Amgen and Novartis are collaboration partners. Absci suits a partner focused on de novo antibodies against new epitopes; Generate suits one looking for a wider protein design platform with a late stage asset.
- Origin-1 designs against epitopes with no known binder.
- A six week cycle from AI design to lab tested candidate.
- ABS-201, with a half life of at least 65 days in interim Phase 1 data.
- Partnerships across oncology, dermatology and animal health.
- Chroma, a protein generation model published in Nature with weights released for academic use.
- GB-0895 in Phase 3 for severe asthma.
- Protein recoding to reduce immune recognition.
- Collaborations with Amgen and Novartis.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Absci and Generate Biomedicines are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Absci | Generate Biomedicines |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2011 | 2018 |
| Headquarters | Vancouver, Washington | Somerville, MA |
| Website | absci.com | generatebiomedicines.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Absci pairs Origin-1, a generative model for de novo antibody design, with lead optimization models and a high throughput wet lab, and develops the results as its own medicines, starting with ABS-201 for pattern hair loss and endometriosis.
Source: AI Health Index, October 2026
Generate Biomedicines designs protein therapeutics with its Chroma model inside a generate, build, measure and learn loop, and develops them itself, led by the anti TSLP antibody GB-0895 in Phase 3 for severe asthma.
Source: AI Health Index, October 2026
Questions buyers ask
How far has each pipeline advanced?
Generate's GB-0895 entered Phase 3 in severe asthma in January 2026. Absci's ABS-201 is in a Phase 1/2a trial, with interim proof of concept data due in the second half of 2026. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
What has each published about its models?
Generate published Chroma in Nature in 2023 and released its weights to academic researchers. Absci names Origin-1 and published a 2026 mAbs paper on fine tuning protein language models for polyreactivity. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Does either license its platform?
Neither sells software. Generate works through confidential collaborations with Amgen and Novartis, and Absci through drug creation partnerships with milestones and royalties. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Generate Biomedicines was founded by Flagship Pioneering and trades on Nasdaq, as does Absci.